Avience Biomedicals Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 78.80x | 683,400 | 53,852,200 | ₹14 Cr |
| NII (HNI) | 🔥 597.72x | 207,000 | 123,727,200 | ₹4 Cr |
| Retail | 🔥 394.72x | 481,200 | 189,940,800 | ₹10 Cr |
| Market Maker | — | 82,200 | — | ₹2 Cr |
| Σ Total | 🔥 267.95x | 1,371,600 | 367,520,200 | ₹29 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 600 | ₹124,800 |
| Retail (Max) | 13 | 7,800 | ₹1,622,400 |
| S-HNI (Min) | 14 | 8,400 | ₹1,747,200 |
| B-HNI (Min) | 67 | 40,200 | ₹8,361,600 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 30 | 17 | 11 |
| EBITDA | 8 | 3 | 1 |
| Profit After Tax | 5 | 2 | 1 |
| Net Worth | 21 | 6 | 4 |
| Total Assets | 44 | 26 | 10 |
| Reserves & Surplus | 17 | 3 | 1 |
| Total Borrowing | 14 | 8 | 3 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh – 15.96
- Funding the working capital requirements of the Company – 8.25
- General Corporate Purposes –
Company Overview
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.
In addition to manufacturing, the Company also act as distributors and traders of medical equipment.
The company's manufacturing unit is situated in Noida, Uttar Pradesh.
The company offers a comprehensive range of diagnostic solutions, including:
- Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test.
- Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit.
- Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY.
- Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer.
- Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM).
As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees
Competitive Strength
- Strong Industry Experience and Expertise.
- Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits.
- Strong distribution network across India and is growing its international footprint.
- Cost-Effective and Affordable Solutions.
- Stringent quality control processes and complies with ISO standards and regulatory approvals.